Wall Street brokerages predict that Thermo Fisher Scientific Inc (NYSE:TMO) will post earnings per share (EPS) of $2.24 for the current fiscal quarter, Zacks reports. Seven analysts have provided estimates for Thermo Fisher Scientific’s earnings, with estimates ranging from $2.20 to $2.28. Thermo Fisher Scientific reported earnings of $2.03 per share in the same quarter last year, which suggests a positive year-over-year growth rate of 10.3%. The firm is scheduled to announce its next earnings report on Thursday, October 26th.

On average, analysts expect that Thermo Fisher Scientific will report full year earnings of $9.24 per share for the current year, with EPS estimates ranging from $9.21 to $9.28. For the next financial year, analysts forecast that the company will report earnings of $10.23 per share, with EPS estimates ranging from $9.85 to $10.81. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that that provide coverage for Thermo Fisher Scientific.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, July 26th. The medical research company reported $2.30 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.27 by $0.03. The business had revenue of $5 billion during the quarter, compared to analyst estimates of $4.92 billion. Thermo Fisher Scientific had a return on equity of 15.97% and a net margin of 11.80%. Thermo Fisher Scientific’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period last year, the company earned $2.03 EPS.

Several research firms have weighed in on TMO. Bank of America Corporation boosted their price target on shares of Thermo Fisher Scientific from $190.00 to $200.00 and gave the stock a “buy” rating in a research note on Tuesday, May 9th. Cleveland Research raised shares of Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a research note on Thursday, July 20th. Jefferies Group LLC boosted their price target on shares of Thermo Fisher Scientific from $160.00 to $175.00 and gave the stock a “hold” rating in a research note on Friday, April 28th. BidaskClub downgraded shares of Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, June 27th. Finally, Citigroup Inc. reissued a “buy” rating and issued a $201.00 price target (up from $182.00) on shares of Thermo Fisher Scientific in a research note on Monday, July 10th. One equities research analyst has rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the stock. Thermo Fisher Scientific currently has a consensus rating of “Buy” and an average target price of $188.56.

Shares of Thermo Fisher Scientific (NYSE:TMO) traded up 0.34% on Friday, reaching $176.33. The company had a trading volume of 752,054 shares. The company’s 50-day moving average is $176.88 and its 200-day moving average is $164.14. The company has a market capitalization of $68.77 billion, a PE ratio of 30.72 and a beta of 1.06. Thermo Fisher Scientific has a one year low of $139.07 and a one year high of $182.87.

The business also recently declared a quarterly dividend, which will be paid on Monday, October 16th. Investors of record on Friday, September 15th will be paid a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a yield of 0.34%. The ex-dividend date of this dividend is Thursday, September 14th. Thermo Fisher Scientific’s payout ratio is currently 10.45%.

TRADEMARK VIOLATION WARNING: “Zacks: Analysts Anticipate Thermo Fisher Scientific Inc (TMO) Will Announce Earnings of $2.24 Per Share” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/04/zacks-analysts-anticipate-thermo-fisher-scientific-inc-tmo-will-announce-earnings-of-2-24-per-share.html.

In related news, CEO Marc N. Casper sold 20,000 shares of the stock in a transaction dated Thursday, June 1st. The shares were sold at an average price of $172.79, for a total value of $3,455,800.00. Following the completion of the transaction, the chief executive officer now directly owns 269,279 shares of the company’s stock, valued at $46,528,718.41. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Stephen Williamson sold 2,500 shares of the stock in a transaction dated Monday, June 5th. The stock was sold at an average price of $176.26, for a total transaction of $440,650.00. Following the completion of the transaction, the chief financial officer now directly owns 37,790 shares of the company’s stock, valued at $6,660,865.40. The disclosure for this sale can be found here. Over the last three months, insiders sold 27,188 shares of company stock valued at $4,702,223. 0.49% of the stock is owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in TMO. State Board of Administration of Florida Retirement System increased its position in Thermo Fisher Scientific by 0.9% in the second quarter. State Board of Administration of Florida Retirement System now owns 580,712 shares of the medical research company’s stock worth $101,317,000 after buying an additional 5,213 shares during the last quarter. Boston Family Office LLC increased its position in Thermo Fisher Scientific by 10.4% in the second quarter. Boston Family Office LLC now owns 22,062 shares of the medical research company’s stock worth $3,849,000 after buying an additional 2,082 shares during the last quarter. Adell Harriman & Carpenter Inc. increased its position in Thermo Fisher Scientific by 15.5% in the second quarter. Adell Harriman & Carpenter Inc. now owns 4,464 shares of the medical research company’s stock worth $779,000 after buying an additional 600 shares during the last quarter. Investment Management of Virginia LLC increased its position in Thermo Fisher Scientific by 0.6% in the second quarter. Investment Management of Virginia LLC now owns 16,791 shares of the medical research company’s stock worth $2,930,000 after buying an additional 105 shares during the last quarter. Finally, HM Payson & Co. increased its position in Thermo Fisher Scientific by 1.9% in the second quarter. HM Payson & Co. now owns 10,865 shares of the medical research company’s stock worth $1,895,000 after buying an additional 200 shares during the last quarter. 86.99% of the stock is owned by institutional investors.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Get a free copy of the Zacks research report on Thermo Fisher Scientific (TMO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Stock Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related stocks with our FREE daily email newsletter.